ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
AviaraDx, Inc. And Massachusetts General Hospital Collaborate In Molecular Cancer Profiling Study
AviaraDx, Inc., a leader in
molecular cancer profiling and formerly known as Arcturus Bioscience, Inc.,
announced today that it has entered into a major research collaboration
with the Massachusetts General Hospital (MGH) Cancer Center to identify
molecular profiles of multiple types of cancer for the development of
diagnostic technologies and tests in the field of cancer drug response
prediction.
Over the next two years, teams at MGH and AviaraDx will conduct a broad
molecular profiling program to determine genes, gene signatures and
polymorphisms that correlate with response to specific therapeutic agents
in a wide range of different cancers. The initiative aims to identify and
commercialize tumor biomarkers that predict which patients may respond to
targeted drugs. MGH and AviaraDx will perform gene sequencing and gene
expression analysis in a large number of cancers. The project results will
not only provide valuable information to help identify patients likely to
respond to a certain cancer drug, but also provide guidance with regard to
a broader range of cancer types likely responding to an established drug.
Daniel A. Haber, MD, PhD, and Jeff Settleman, PhD, of MGH have
extensive experience in the identification of genetic markers associated
with drug response. Most recently, they reported the identification of a
gene mutation that appears to identify those lung cancer patients who will
likely respond to the cancer drug Iressa(R). (1)
Mark Erlander, Ph.D. and Xiao-Jun Ma, Ph.D., of AviaraDx have developed
the company's Molecular Cancer Identification (MCID) technology, which has
been licensed to clinical laboratory partners in the US and Europe.
"The MGH Cancer Center is a world leading medical research center, and
we are pleased to be collaborating with them in a program that may result
in the development of molecular diagnostic tests for drug response
prediction in cancer," said Antonius Schuh, Ph.D., Chief Executive Officer
of AviaraDx, Inc. "Transforming the molecular basis of cancer into
diagnostic technologies with proven clinical utility is the core focus for
AviaraDx. Our molecular cancer identification (MCID) and breast cancer
profiling (BCP) technologies are impressive achievements in this space.
"Our goal is the development of a rational basis for the selection of a
specific drug regimen in a given patient," said Dr. Haber, who is the
director of the MGH Cancer Center. "We are hopeful that this collaboration
will generate technologies of relevant molecular diagnostic tests for
predicting what therapy is best suited for specific patients."
About AviaraDx, Inc.
AviaraDx, Inc., formerly Arcturus Bioscience, Inc., is focused on
developing and commercializing diagnostic technologies for molecular cancer
profiling. AviaraDx leverages its technological leadership position in the
analysis of cancer biopsies and proprietary bioinformatic methodologies to
discover and commercialize molecular diagnostic products. The molecular
diagnostic market segment of the diagnostic market is projected to grow at
a compound annual growth rate of greater than 25% over the next decade and
AviaraDx is targeting this market opportunity with three first-in-class
molecular cancer diagnostic technologies: Molecular Cancer Identification
(MCID), Breast Cancer Profiling (BCP) and Drug Response Profiling (DRP).
AviaraDx estimates that the addressable U.S. market for its products and
services is approximately $3 billion and has already licensed its MCID and
BCP technologies for specific clinical indications and for defined
detection platforms to diagnostic laboratories in the U.S. and Europe in
order drive early market penetration and acceptance. AviaraDx has recently
relocated its headquarters from Mountain View, California to Carlsbad,
California. Please visit the AviaraDx website at http://www.aviaradx.com
for more information.
About Massachusetts General Hospital
Massachusetts General Hospital, established in 1811, is the original
and largest teaching hospital of Harvard Medical School. Its dedication to
the treatment of cancer dates back to 1925, when the MGH opened the
nation's first tumor clinic. Over the decades, the hospital has become
widely known for its leadership in cancer surgery and radiation therapy.
The MGH conducts the largest hospital-based research program in the United
States, with an annual research budget of nearly $500 million and major
research centers in AIDS, cardiovascular research, cancer, cutaneous
biology, medical imaging, neurodegenerative disorders, transplantation
biology and photomedicine. In 1994, MGH and Brigham and Women's Hospital
joined to form Partners HealthCare, an integrated health care delivery
system.
(1) IRESSA(R) is a trademark of the AstraZeneca group of companies.
AviaraDx, Inc.
http://www.aviaradx.com/
AviaraDx, Inc ªi Massachusetts General Hospital colabora Molecular Cancer Profiling Studiul - AviaraDx, Inc. And Massachusetts General Hospital Collaborate In Molecular Cancer Profiling Study - articole medicale engleza - startsanatate